Therapy: The risk of herpes zoster: Another cost of anti-TNF therapy?

Tim Bongartz; Robert Orenstein

doi:10.1038/nrrheum.2009.120

Therapy: The risk of herpes zoster: Another cost of anti-TNF therapy?

Tim Bongartz, Robert Orenstein

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Several studies have shown that tumor necrosis factor (tNF) inhibitors are associated with an overall increased risk of serious infections compared with standard immunosuppressive regimens in patients with rheumatoid arthritis (ra). a study by Strangfeld et al. adds specificity by showing a moderately increased risk of herpes zoster in patients receiving anti-tNF antibody treatment, and raises the question of whether live zoster vaccines should be utilized in this patient group.

Original language	English (US)
Pages (from-to)	361-363
Number of pages	3
Journal	Nature Reviews Rheumatology
Volume	5
Issue number	7
DOIs	https://doi.org/10.1038/nrrheum.2009.120
State	Published - Jul 2009

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1038/nrrheum.2009.120

Cite this

@article{d072d55239fd407ca16a27a399aa2e7b,

title = "Therapy: The risk of herpes zoster: Another cost of anti-TNF therapy?",

abstract = "Several studies have shown that tumor necrosis factor (tNF) inhibitors are associated with an overall increased risk of serious infections compared with standard immunosuppressive regimens in patients with rheumatoid arthritis (ra). a study by Strangfeld et al. adds specificity by showing a moderately increased risk of herpes zoster in patients receiving anti-tNF antibody treatment, and raises the question of whether live zoster vaccines should be utilized in this patient group.",

author = "Tim Bongartz and Robert Orenstein",

year = "2009",

month = jul,

doi = "10.1038/nrrheum.2009.120",

language = "English (US)",

volume = "5",

pages = "361--363",

journal = "Nature Reviews Rheumatology",

issn = "1759-4790",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Therapy

T2 - The risk of herpes zoster: Another cost of anti-TNF therapy?

AU - Bongartz, Tim

AU - Orenstein, Robert

PY - 2009/7

Y1 - 2009/7

N2 - Several studies have shown that tumor necrosis factor (tNF) inhibitors are associated with an overall increased risk of serious infections compared with standard immunosuppressive regimens in patients with rheumatoid arthritis (ra). a study by Strangfeld et al. adds specificity by showing a moderately increased risk of herpes zoster in patients receiving anti-tNF antibody treatment, and raises the question of whether live zoster vaccines should be utilized in this patient group.

AB - Several studies have shown that tumor necrosis factor (tNF) inhibitors are associated with an overall increased risk of serious infections compared with standard immunosuppressive regimens in patients with rheumatoid arthritis (ra). a study by Strangfeld et al. adds specificity by showing a moderately increased risk of herpes zoster in patients receiving anti-tNF antibody treatment, and raises the question of whether live zoster vaccines should be utilized in this patient group.

UR - http://www.scopus.com/inward/record.url?scp=70349561257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349561257&partnerID=8YFLogxK

U2 - 10.1038/nrrheum.2009.120

DO - 10.1038/nrrheum.2009.120

M3 - Article

C2 - 19568250

AN - SCOPUS:70349561257

SN - 1759-4790

VL - 5

SP - 361

EP - 363

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

IS - 7

ER -

Therapy: The risk of herpes zoster: Another cost of anti-TNF therapy?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this